Adlai Nortye

21 articles with Adlai Nortye

• Oncolytics Biotech® Partner Adlai Nortye Advances Chinese Bridging Trial of Pelareorep-Paclitaxel Combination Treatment in Breast Cancer to Final Dosing Cohort

  3/24/2022

    [24-March-2022]   First two cohorts indicate pelareorep in combination with paclitaxel was well-tolerated with no new safety signals observed to date Trial is designed to satisfy regulatory requirements and accelerate pelareorep's development in large and rapidly growing pharmaceutical markets, including China , Hong Kong , Macau , Taiwan , Singapore , and South Korea Final cohort's

• Adlai Nortye Announces Appointment of Dr. Victoria Demby as Senior Vice President of Global Regulatory Affairs

  3/14/2022

  Adlai Nortye Ltd., a clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies, is pleased to welcome new senior level talent to its dynamic global leadership team.

• Adlai Nortye Announces Publication of Preclinical Research of AN3025 (anti-hTNFR2）in Frontiers in Immunology

  2/21/2022

  Adlai Nortye Ltd. announced the publication of preclinical research of AN3025 (anti-hTNFR2）in the peer-reviewed journal Frontiers in Immunology.

• Oncolytics Biotech® Partner Adlai Nortye Advances to the Second Dose Escalation Cohort of the Chinese Bridging Trial Evaluating Pelareorep-Paclitaxel Combination Treatment in Breast Cancer

  1/27/2022

   Oncolytics Biotech today announced that its partner Adlai Nortye has advanced to the second of three dose escalation cohorts in the bridging clinical trial evaluating the safety, tolerability, and preliminary efficacy of pelareorep-paclitaxel combination therapy in Chinese patients with advanced or metastatic breast cancer.

• Adlai Nortye Announces Global License-out Agreement with Biotime for Several Products Including PD-L1 Inhibitor (AN4005) and Anti-hTNFR2 Antibody (AN3025)

  1/26/2022

  Adlai Nortye Ltd. announced that it has entered into a Global License Agreement with Xiamen Biotime Biotechnology Co., Ltd. ("Biotime") for several compounds.

• Adlai Nortye Announces First Patient Dosed in Phase Ia Clinical Trial of AN2025 and AN0025 in Combination with atezolizumab for Advanced Solid Tumors

  9/8/2021

  Adlai Nortye, a global biopharmaceutical company focused on developing innovative oncology drugs, announced that the first patient has been dosed in the Phase Ia clinical trial in the U.S. to evaluate the triple combination of AN2025, AN0025 and atezolizumab in patients with locally advanced/metastatic tumors.

• Adlai Nortye Announces Formation of its New Scientific Advisory Board

  3/8/2021

  Adlai Nortye, a global clinical-stage biopharmaceutical company, announced the formation of its new Scientific Advisory Board comprised of five internationally renowned experts.

• Adlai Nortye Announces First Patient Dosed in Phase 1b Clinical Trial of AN0025 (EP4 Antagonist) in Combination with Merck's KEYTRUDA® (pembrolizumab) for Advanced Solid Tumors

  8/24/2020

  Adlai Nortye Ltd., a global clinical-stage biopharmaceutical company announced that the first patient has been dosed in a phase 1b clinical trial to evaluate AN0025, an investigational, potentially first in class oral EP4 antagonist, in combination with Merck's KEYTRUDA® in patients with locally advanced/metastatic solid tumors.

• Adlai Nortye Presents Encouraging Phase 1b Study Data of AN0025 (an Oral EP4 Antagonist) for Locally Advanced Rectal Cancer at ESMO 2019

  9/30/2019

  Adlai Nortye Ltd. announced at the European Society for Medical Oncology 2019 Congress the first results from a phase 1b neoadjuvant study of AN0025, an investigational, potentially first in class oral EP4 antagonist.

• Adlai Nortye Receives NMPA Approval for Pelareorep (AN1004) in China to Initiate Phase III Clinical Trials

  3/21/2019

  Adlai Nortye Ltd., a global clinical-stage biopharmaceutical company, announced that it has received a clearance from the National Medical Products Administration of China for initiating the open-label, randomized, multicenter, global phase III clinical trial for pelareorep in combination with paclitaxel in patients with advanced/ metastatic breast cancer in China.

• Adlai Nortye's Buparlisib (AN2025) Set to Become a Potential Treatment for Anti-PD-1 Non-responding Tumor in HNSCC

  3/15/2019

  Adlai Nortye Ltd., a global clinical-stage biopharmaceutical company released the animal model data of Buparlisib at the 7th ICHNO, the International Conference on Innovative Approaches in Head & Neck Oncology.

• Adlai Nortye Announces Clinical Collaboration with Merck to Evaluate Adlai Nortye's AN0025 (EP4 Antagonist) in Combination with KEYTRUDA® (pembrolizumab) in Patients with Solid Tumors

  1/3/2019

  Adlai Nortye Ltd. today announced that it has entered into a clinical collaboration with Merck (known as MSD outside the US and Canada) to evaluate the combination of Adlai Nortye's AN0025 (EP4 Antagonist) and Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with solid tumors.

• Adlai Nortye Opens New US Headquarters, Solidifying its Position in the Global Pharma Industry

  9/25/2018

  Adlai Nortye Ltd. announced the official opening of their new USA headquarters today during a ceremony at the Biotechnology Development Center in North Brunswick, New Jersey.

• 

  Novartis’s Breast Cancer Drug Looks Promising in Phase III Trial, Despite Category’s Troubling Hi...

  8/23/2018

  Novartis announced that its BYL719 (alpelisib) met the primary endpoint of progression-free survival (PFS) in its Phase III SOLAR-1 trial. The drug is an alpha-specific PI3K inhibitor, a category of cancer drugs that has a troubling history of adverse events.

• Adlai Nortye Eyes Global Expansion With the Opening of Its First International Site in USA

  8/16/2018

  Adlai Nortye Ltd. announced the opening of its first US site in Boston, Massachusetts.

• Adlai Nortye Announces Engagement of Lars E. Birgerson, M.D., Ph.D., as CDO and President/CEO of Adlai Nortye USA

  8/6/2018

  Adlai Nortye Biopharma Co., Ltd. announced that Lars E. Birgerson, M.D., Ph.D., joins the company as Chief Development Officer (CDO) and President & CEO of Adlai Nortye USA Inc on July 1st.

• Adlai Nortye announces the publication of the Biomarker Analysis From BERIL-1, the Buparlisib study in HNSCC

  7/30/2018

  Adlai Nortye Corporation, a leading biotech company in China, today announced a biomarker analysis publication by the investigators from the phase II study BERIL-1 Buparlisib/Paclitaxel vs Paclitaxel in 2nd Line HNSCC. The study was published by Clinical Cancer Research, June 2018, volume 24, issue 11, titled "Molecular Alterations and Buparlisib Efficacy in Patients With Squamous Cell Carcinoma of the Head and Neck: Biomarker Analysis From BERIL-1".

• Adlai Nortye Announce Global License Agreement for Buparlisib (BKM120)

  7/10/2018

  Adlai Nortye Biopharma Co., Ltd. ("Adlai Nortye" or "the Company"), a biopharmaceutical company dedicated to discovering and commercializing new drugs in the field of oncology/immuno-oncology, announced today that it has entered into a Global License Agreement ("the Agreement") with Novartis Pharma AG, a global pharmaceutical company.

• Adlai Nortye Raises $53M in Series B

  7/5/2018

  Adlai Nortye Biopharma Co., Ltd. ("Adlai Nortye" or "the Company"), a biopharmaceutical company, announced that it has raised $53 million in a Series B financing round.

• Eisai Enters Into Licensing Agreement With Adlai Nortye for Potential Anticancer Agent E7046

  1/19/2018

  E7046 is an orally administered, selective EP4 receptor antagonist discovered by Eisai's U.S. Andover research facility.